The Ultimate Rivalry: The University of Oklahoma vs. Oklahoma State University

The first published evidence from humans that semaglutide specifically reduces the symptoms of Alcohol Use Disorder (AUD) has been published in The Journal of Clinical Psychiatry and outlines an innovative collaboration between clinicians and scientists at the University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences. The paper elucidates the outcomes of six patients who received semaglutide during treatment for weight loss, demonstrating a significant and noteworthy decrease in their Alcohol Use Disorders Identification Test (AUDIT) scores.

The paper is titled “Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.” This collaboration has the potential to impact the lives of individuals struggling with AUD.

Semaglutide, known for the treatment of diabetes under the name Ozempic, and weight loss under the name Wegovy, has attracted attention due to its potential broader applications, including its effect on addictive behaviors such as reducing drug craving and alcohol consumption. Pre-clinical research has demonstrated that semaglutide is associated with marked decreases in drug and alcohol consumption, echoing the significant reductions experienced by patients taking the drug for diabetes and weight loss who reported a lessened urge to drink alcohol.

“This research marks a significant step forward in understanding the potential therapeutic applications of semaglutide in addiction medicine,” said the lead author, Dr. Jesse Richards, director of Obesity Medicine and assistant professor of Medicine at OU-TU School of Community Medicine.

Dr. Kyle Simmons, the paper’s senior author and professor of Pharmacology & Physiology at OSU-Center for Health Sciences noted that this case series evidence paves the way for gold-standard placebo-controlled clinical trials such as the one he is currently conducting in Tulsa at the OSU Hardesty Center for Clinical Research and Neuroscience.

Called STAR (Semaglutide Therapy for Alcohol Reduction), the clinical trial is funded by the Hardesty Family Foundation and OSU-CHS. A sister study is also currently underway in Baltimore funded by the National Institute on Drug Abuse (NIDA).

The researchers emphasized the need for further investigation through larger, controlled studies to validate and expand upon these initial findings. Until the results of future placebo-controlled clinical trials are available, the authors believe that healthcare providers should point patients toward established behavioral treatments and medications that have been validated by the FDA for alcohol use disorder.

Key Takeaways from the Research:

Semaglutide Treatment and Alcohol Use Disorder: The study revealed a marked reduction in Alcohol Use Disorder Identification Test (AUDIT) scores in all six patients who received semaglutide treatment in the course of pharmacotherapy for weight loss. The results suggest a potential role for this medication in the management of Alcohol Use Disorder.

Implications for Future Research: The findings open new avenues for future research into the use of glucagon-like peptide-1 medications, such as semaglutide, in the treatment of addictive behaviors.

Collaborative Research Model: This collaboration between The University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences is an example of the potential when clinicians and scientists collaborate to explore innovative solutions to complex health care challenges.